Zinger Key Points
- Adjusted operating income was $199 million, compared to $204 million for the same period a year ago.
- The guidance reflects recent changes in foreign currency exchange rates and assumes 2% organic revenue growth.
- Get Pro-Level Earnings Insights Before the Market Moves
On Monday, Revvity Inc. RVTY reported second-quarter sales of $691.69 million, down from $709.07 million, beating the consensus of $690.36 million.
The life sciences and diagnostics company earned second-quarter adjusted EPS of $1.22, beating the consensus of $1.12.
Revvity is an American company in the life sciences and diagnostics business focused on selling to the pharmaceutical and biotechnology industries.
The company reported GAAP earnings per share of $0.45 compared to $0.28 a year ago.
Adjusted operating income was $199 million, compared to $204 million for the same period a year ago. The adjusted operating profit margin was 28.7%compared to 28.8% a year ago.
Life Sciences revenue was $314 million, down 7% on a reported basis. Organic revenue decreased 6%.
Diagnostics sales increased 1% year-over-year to $378 million, and organic revenue increased 3%.
Guidance: Revvity updates its fiscal year 2024 sales guidance to $2.77 billion—$2.79 billion, compared to prior guidance of $2.76 billion—$2.82 billion and consensus of $2.79 billion.
The guidance reflects recent changes in foreign currency exchange rates and assumes 2% organic revenue growth.
The company forecasts 2024 adjusted EPS of $4.70-$4.80 versus the prior guidance of $4.55-$4.75 and a consensus of $4.63.
Price Action: RVTY stock is up 2.78% to $118.46 at the last check on Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
